Trial intelligence / Profile preview

Estradiol Valerate/Dienogest for Dysfunctional Uterine Bleeding

NCT00307801Phase 3Completed

Sponsor
Bayer
Start
Feb 2006
Primary completion
May 2008
Modality
Small Molecules
Countries
10
01

Overview

Phase 3, randomised, double-blind trial in dysfunctional uterine bleeding (DUB) comparing Estradiol valerate/Dienogest with Placebo (2 arms). Primary endpoint: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms at 90 days. Started Feb 2006; status: completed.

02

Drugs

estradiol valerate + dienogest
03

Conditions

dysfunctional uterine bleeding (DUB)

Beyond the preview

Go deeper on NCT00307801.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00307801.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call